ABUS
Arbutus Biopharma Corp
Arbutus Biopharma Corp
$ABUS reports AB-161 Phase 1 clinical trial initiation for chronic HBV treatment
Arbutus Biopharma has initiated a Phase 1 trial for its oral RNA destabilizer, AB-161, to treat chronic hepatitis B virus infection. The trial will focus on safety, tolerability, and pharmacokinetics and is expected to release initial data in H2 2023. Chronic HBV infection affects over 290 million people globally, with around 820,000 deaths each year due to complications. Arbutus is dedicated to developing an all-oral treatment regimen for chronic HBV and plans to share the trial's initial results. However, cautionary statements related to issues can have a significant impact on future outcomes.
9d ago
$ABUS